CA Patent

CA3121191A1 — Optimized mrna encoding cas9 for use in lnps

Assigned to CRISPR Therapeutics AG · Expires 2020-06-04 · 6y expired

What this patent protects

The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell. Some embodiments of the disclosure relate to compositions and…

USPTO Abstract

The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell. Some embodiments of the disclosure relate to compositions and methods for editing the genome of a cell, which involve contacting the cell with an LNP composition as described herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA3121191A1
Jurisdiction
CA
Classification
—
Expires
2020-06-04
Drug substance claim
No
Drug product claim
No
Assignee
CRISPR Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.